Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemia

the ONA take:

According to a new study published in the journal JAMA Oncology, researchers from Ohio State University in Columbus, Ohio, have found that about 10% of patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib discontinued therapy because of disease progression during clinical studies.

Ibrutinib is a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA) indicated for the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia who have received at least one prior therapy and Waldenstrom's macroglobulinemia.

For the study, researchers analyzed the characteristics of patients who discontinued ibrutinib treatment and their outcomes. Results showed that after a median follow-up of 20 months, 75% of 308 patients remained on ibrutinib treatment, 10% discontinued treatment due to disease progression, 9% discontinued treatment due to infection, about 3% discontinued for other adverse events, and 3% due to other medical events.

Findings also showed that patients had a poor prognosis after discontinuation of ibrutinib therapy, especially those with Richter's transformation, in which the cancer becomes an aggressive lymphoma.

Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemia
Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemia
About 10 percent of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase (BTK) inhibitor drug ibrutinib because of disease progression during clinical trials, according to a study published online by JAMA Oncology.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs